![Robin Isaacs](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Historique de carrière de Robin Isaacs
Anciens postes connus de Robin Isaacs
Sociétés | Poste | Début | Fin |
---|---|---|---|
Entasis Therapeutics, Inc.
![]() Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Directeur Technique/Scientifique/R&D | 01/07/2015 | 04/11/2019 |
ENTASIS THERAPEUTICS HOLDINGS INC. | Directeur Technique/Scientifique/R&D | 01/07/2015 | 04/11/2019 |
University of Mississippi Medical Center | Corporate Officer/Principal | - | - |
Formation de Robin Isaacs
Auckland University | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 4 |
Nouvelle-Zélande | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Entasis Therapeutics, Inc.
![]() Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Health Technology |
Entasis Therapeutics Holdings, Inc.
![]() Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
- Bourse
- Insiders
- Robin Isaacs
- Expérience